Go to the list of all blogs
Allana's Avatar
published in Blogs
Oct 25, 2026
TickeronGET DAILY SIGNALS
XAR ETF: Can the Aerospace & Defense Fund Reach $250?

XAR ETF: Can the Aerospace & Defense Fund Reach $250?

Key Takeaways

  • XAR is the SPDR S&P Aerospace & Defense ETF, an equal-weighted fund tracking the S&P Aerospace & Defense Select Industry Index and issued by State Street Global Advisors.
  • The $250 objective is a technical and valuation milestone drawn from public discussion, not an analyst consensus—analysts publish targets on the fund's underlying stocks, not on the ETF itself.
  • With the fund recently trading near $222, reaching $250 would require roughly a 13% advance, a modest move relative to its 52-week range.
  • XAR sits near its 52-week low of $215.02 and well below its 52-week high of $297.79, leaving ample room above but signaling weak recent momentum.
  • Supporting factors include rising global defense budgets, geopolitical demand, and broad equal-weight diversification across defense primes and mid-cap aerospace growth names.
  • Principal risks include an above-benchmark valuation, a multi-month downtrend, federal budget uncertainty, and interest-rate sensitivity.
  • Readers can explore additional pages for Major News, Today's Price Move, Forecast, and Earnings.
  • Interested investors can also explore Trending AI Robots for additional market insight.

How the $250 Target Came Into View

Because XAR is an exchange-traded fund rather than a single stock, sell-side analysts do not issue direct price targets on the fund itself. As a result, no official analyst consensus price target exists for XAR, and none is used here. Instead, the $250 figure reflects a realistic technical and valuation milestone that appears in public market discussion: a clean psychological level that would mark a partial recovery from the fund's 52-week low toward its 52-week high of $297.79.

For context, data providers such as TipRanks derive an "implied" target by aggregating analyst targets on XAR's roughly 48 underlying holdings. Those holdings-derived figures have been cited near $350 in public commentary, but that number was calculated against a materially higher fund price and reflects sell-side optimism on the constituent stocks—typically running about 12 months out—rather than a forecast for the ETF. It should not be read as a price objective for XAR.

Current Market Position and Path Toward the Target

In recent sessions XAR has traded around $222, down roughly 7% so far in 2026 and close to the low end of a 52-week range spanning $215.02 to $297.79. A move to $250 implies upside of about 13%, which qualifies as a modest move in percentage terms, though it would require reversing a persistent multi-month downtrend.

The fund's equal-weight structure is a defining feature: no single holding dominates, with top positions such as Axon Enterprise (AXON), RTX Corporation (RTX), Lockheed Martin (LMT), General Dynamics (GD), GE Aerospace (GE), and HEICO (HEI) generally each representing only about 3% of assets. This diversification limits single-stock risk but also means the fund tends to trade as a broad sector bet on aerospace and defense spending.

What Could Support a Move Toward the Target

  • Defense spending growth. Global military expenditure is expected to reach about $2.6 trillion in 2026, and NATO members continue legislating higher budgets toward and above 2% of GDP.
  • US budget proposals. Public discussion of substantially higher US defense outlays—including proposals for missile-defense and naval programs—could expand the addressable market for many XAR constituents.
  • Geopolitical demand. Sustained conflict and the need to replenish weapons stockpiles support order backlogs across the sector.
  • Diversified exposure. Equal weighting blends mature defense primes with mid-cap growth names tied to drones, space, and defense electronics, offering multiple potential catalysts rather than reliance on one story.

What Could Prevent the Target From Being Reached

  • Elevated valuation. The fund's portfolio trades at a premium to its benchmark, and multiple compression toward sector-average levels could offset even solid earnings growth.
  • Momentum reversal. XAR has fallen from its March 2026 peak, and a sustained downtrend can take time to repair even when fundamentals improve.
  • Budget uncertainty. Delays or downward revisions to defense appropriations, or shifting political priorities, could pressure sentiment across the entire sector.
  • Rate sensitivity. As an equity fund holding cyclical industrial names, XAR can be sensitive to interest-rate expectations and broader risk appetite.

Technical Levels and Market Structure

XAR's 52-week low near $215 acts as a key support level, and a break below it would open further downside. On the upside, the $250 psychological level sits before a larger resistance zone that includes the fund's longer-term moving averages, cited in public technical commentary near $241 (200-day) and $272 (50-day). Reclaiming those levels would be an important step toward validating a durable recovery, while the 52-week high of $297.79 remains the longer-term reference point.

Time Horizon and What Investors Should Monitor

Analyst targets on the underlying holdings generally reflect a roughly 12-month horizon, but no equivalent timeline applies to the $250 technical objective, which is best treated as a medium-term milestone rather than a dated forecast. Investors should monitor upcoming earnings and guidance from major constituents, defense appropriations and budget negotiations, NATO and global spending commitments, interest-rate decisions from the FOMC (Federal Open Market Committee), and ETF fund flows and holdings changes, which can signal shifting sector sentiment.

Exploring AI Daily Buy/Sell Signals

In my analysis of XAR, I also checked this using Tickeron's AI Daily Buy/Sell Signals to see how the ETF compares to others in the industry and to track potential shifts in momentum more systematically.

Final Assessment

Whether XAR can reach $250 depends less on any single catalyst than on whether the fund can arrest its recent decline and rebuild investor confidence. The roughly 13% advance required is modest in absolute terms, and the structural case—rising defense budgets and diversified exposure—remains intact. At the same time, an above-benchmark valuation, persistent downward momentum, and budget and rate uncertainty are meaningful obstacles. Because analysts do not publish direct targets on ETFs, the $250 figure is best understood as a technical milestone rather than a consensus expectation, and investors should monitor sector earnings, spending legislation, and technical levels before drawing conclusions. No outcome is guaranteed, and this analysis makes no investment recommendation.

Using Tickeron AI Tools for Research

I've found Tickeron's AI Daily Buy/Sell Signals helpful for monitoring ETFs like XAR alongside manual review. The platform applies AI to scan thousands of instruments and flag potential Buy, Sell, or Hold signals based on technical and market shifts, which can complement an investor's own process without replacing it. This has been one way I've stayed on top of sector trends efficiently.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: XAR

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


XAR sees MACD Histogram just turned negative

XAR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 18, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 39 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XAR as a result. In 68 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

XAR moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XAR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

XAR broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for XAR entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where XAR's RSI Indicator exited the oversold zone, 24 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +1.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where XAR advanced for three days, in 289 of 328 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Aerospace & Defense Select Industry Index. In seeking to track the performance of the S&P Aerospace & Defense Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the aerospace and defense segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the State Street SPDR S&P Aerospace & Defense ETF (XAR) ETF is 38.82B. The market cap for tickers in the group ranges from 419.92M to 335.38B. GE holds the highest valuation in this group at 335.38B. The lowest valued company is SPCE at 419.92M.

High and low price notable news

The average weekly price growth across all stocks in the State Street SPDR S&P Aerospace & Defense ETF (XAR) ETF was 2%. For the same ETF, the average monthly price growth was 26%, and the average quarterly price growth was 48%. AVEX experienced the highest price growth at 10%, while SPCE experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the State Street SPDR S&P Aerospace & Defense ETF (XAR) ETF was 17%. For the same stocks of the ETF, the average monthly volume growth was 55% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 59
Price Growth Rating: 59
SMR Rating: 64
Profit Risk Rating: 64
Seasonality Score: -6 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.